Home

Chris Degnan

CIK 1741968 · Chief Financial Officer · last filed 2026-02-03

Chris Degnan is a Chief Financial Officer who has filed 11 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for URGN, was dated Feb 3, 2026. Across all open-market trades the lifetime net is +$27.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $97.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$97.9K

Companies

3

Total Filings

11

Lifetime Open-Market Net

$27.5K

Filer Profile

Reported Address
C/O VERRICA PHARMACEUTICALS INC.
10 NORTH HIGH STREET, SUITE 200
WEST CHESTER, PA 19380
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
URGN Chief Financial Officer 2,280 $42.31 $96.5K -$37.1K 3 2026-02-03
Galera Therapeutics, Inc. (GRTX) Delisted Chief Financial Officer 50 $17.60 $880 $19.6K 6 2023-03-14
VRCA Chief Financial Officer 300 $4.91 $1.5K $45.0K 2 2019-03-04

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-03 URGN Grant (A) — $0 EDGAR
2025-10-09 URGN Mixed +2,280 -$37.1K EDGAR
2024-10-09 URGN Grant (A) — $0 EDGAR
2023-03-14 Galera Therapeutics, Inc. (GRTX) Delisted Buy (P) +10,000 $19.6K EDGAR
2023-02-28 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
2022-03-02 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
2021-01-28 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
2020-02-04 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
2019-11-08 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
2019-03-04 VRCA Grant (A) — $0 EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.